Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

6.600 -0.010 (-0.15%)
Streaming Delayed Price Updated: 11:42 AM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Arvinas (ARVN) Shares Are Seeing Blue Skies
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement. 
Via Benzinga
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Ratings for Arvinas
Via Benzinga
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Analyst Expectations for Arvinas's Future
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
7 Analysts Have This to Say About Arvinas
Via Benzinga
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
Via Benzinga
What 8 Analyst Ratings Have To Say About Arvinas
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic  
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Looking Into Arvinas's Return On Capital Employed
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Arvinas: Q1 Earnings Insights
Via Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
Wells Fargo raised the price target for Stanley Black & Decker, Inc. (NYSE: SWK) from $85 to $90. Wells Fargo analyst Joe O'Dea maintained an Equal-Weight rating. Stanley Black & Decker shares rose 3%... 
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows. 
Via Benzinga
Looking Into Arvinas's Return On Invested Capital
Via Benzinga
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday. 
Via Benzinga
Analyst Ratings for Arvinas
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Burlington shares fell 0.1% to... 
Via Benzinga
Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk
  Telsey Advisory Group raised the price target on Abercrombie & Fitch Co. (NYSE: ANF) from $25 to $27. Abercrombie & Fitch shares fell 1.2% to $22.34 in pre-market trading. 
Via Benzinga
Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting
Via Benzinga
Carvana, Crocs And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.